SCHEMBL2148990

SCHEMBL2148990

O/N=C/c1c(-c2ccccc2)n(-c2ccc(O)cc2)c2cccc(F)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 5/20 0.40
ESR1 P03372 4/20 0.40
GRIA1 P42261 1/20 0.38
CACNG8 Q8WXS5 1/20 0.38
CACNG2 Q9Y698 1/20 0.38
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
IL1R1 P14778 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HTT P42858 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2148993 1.00 ESR2 (0.40) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2146435 0.81 MAPT (0.46) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2146432 0.81 MAPT (0.46) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2146839 0.79 LMNA (0.37) GRIA1CACNG8CACNG2LMNAMEN1
SCHEMBL2146834 0.79 LMNA (0.37) GRIA1CACNG8CACNG2LMNAMEN1
SCHEMBL1036114 0.78 ALDH1A1 (0.44) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2146284 0.78 ERN1 (0.36) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2146286 0.78 ERN1 (0.36) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2144967 0.78 GRIA1 (0.39) ESR2ESR1GRIA1CACNG8CACNG2
SCHEMBL2290898 0.78 GRIA1 (0.39) ESR2ESR1GRIA1CACNG8CACNG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US disclosed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP disclosed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 ESR2 4/4885ESR1 1/4885GRIA1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.